What Happened?
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) jumped 4.1% in the afternoon session after the company announced that its oncology testing portfolio is now available through the Epic Aura platform, integrating its services with a major electronic health record (EHR) system.
This integration allowed physicians to order NeoGenomics' comprehensive suite of tests and view results within the same system they used to manage patient care. The move was designed to lower barriers for hospitals and health systems to use the company's services.
According to the announcement, this streamlined approach could lead to a 20-30% increase in test adoption per site. This represented a significant step in the company's digital health strategy, strengthening its connectivity with oncology practices and supporting the delivery of next-generation diagnostic capabilities.
After the initial pop the shares cooled down to $8.25, up 4.2% from previous close.
Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
NeoGenomics’s shares are extremely volatile and have had 31 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 12 months ago when the stock dropped 34.8% on the news that the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations.
Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-year revenue guidance exceeded Wall Street's estimates. Overall, this quarter was mixed. The areas below expectations seemed to be driving the move.
NeoGenomics is down 29.9% since the beginning of the year, and at $8.25 per share, it is trading 37.6% below its 52-week high of $13.22 from January 2026. Investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at only $159.51.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
